World Economic Forum’s EDISON Alliance Impacts Over 1 Billion Lives, Accelerating Global Digital Inclusion.
The EDISON Alliance has connected over 1 billion people globally to essential digital services like healthcare, education and finance through a network of 200+ partners in over 100 countries.
Investments in bridging the universal digital divide could bring $8.7 trillion usd/ $11.7 trillion cad in benefits to developing countries, home to more than 70% of the Alliance’s beneficiaries.
The Alliance’s 300+ partner initiatives, including digital dispensaries in India, economy digitalization programmes in Rwanda and blended learning in Bangladesh, continue to shape a digitally equitable society.
Follow the Sustainable Development Impact Meetings 2024 here and on social media using #SDIM24.
New York, USA, September 2024 – The EDISON Alliance, a World Economic Forum initiative, has successfully connected over 1 billion people globally – ahead of its initial 2025 target – to essential digital services in healthcare, education and finance in over 100 countries. Since its launch in 2021, the Alliance has united a diverse network of 200+ partners from the public and private sectors, academia and civil society to create innovative solutions for digital inclusion.
Despite living in a digitally connected world, 2.6 billion people are currently not connected to the internet.
This digital exclusion impacts access to healthcare, financial services and education, contributing to significant economic costs for both the individuals involved and their countries’ economies.
Klaus Schwab- German mechanical engineer, economist and founder of the World Economic Forum.
“Ensuring universal access to the digital world is not merely about connectivity, but a fundamental pillar of equality and opportunity,” said Klaus Schwab, Founder and Chairman of the World Economic Forum. “Let us reaffirm our commitment to ensuring that every individual, regardless of their geographic or socioeconomic status, has access to meaningful connectivity.”
The Alliance has made substantial progress in South Asia and Africa.
In Madya Pradesh, India, The EDISON Alliance fostered the Digital Dispensaries initiative, a collaboration between the Apollo Hospitals Group and a US telecom infrastructure provider. This partnership has successfully delivered quality and affordable healthcare, improving patient engagement, addressing gender health disparities and optimizing patient convenience, and making it a scalable model for delivering patient-centric healthcare through digital solutions. Other partner projects improved digital access through economy digitalization programmes in Rwanda, provided solutions for bridging the education gap in Bangladesh with blended learning techniques and explored solutions to reduce financial exclusion in Pakistan.
“Everybody, no matter where they were born or where they live, should have access to the digital services that are essential for life in the 21st century,” said Hans Vestberg, Chair of the EDISON Alliance, Chairman and CEO of Verizon. “Making sure that everybody can get online is too big a challenge for any one company or government, so the EDISON Alliance brings people together to find practical, community-based solutions that can scale globally.”
By driving digital inclusion through its 300+ partner initiatives, the Alliance contributes to unlocking the immense potential of the digital economy. Achieving universal internet access by 2030 could require $446 billion usd/ $600 billion cad, but would yield $8.7 trillion usd/ $11.7 trillion cad in benefits for developing countries. This highlights the significant potential of digital inclusion to drive economic growth and improve lives. The EDISON Alliance has made substantial contributions to this goal, with over 70% of its impact concentrated in developing nations.
The milestone of connecting 1 billion lives was initially targeted for 2025.
Achieving this ahead of schedule demonstrates the effectiveness of its partners, through collaboration and targeted projects, in bridging the digital divide and providing access to critical services to underserved communities.
Beyond digital access, the rapidly evolving technological landscape – marked by such advancements as artificial intelligence, presents opportunities and challenges. The EDISON Alliance remains committed to ensuring that marginalized communities can fully benefit from these developments and avoid being left behind. As technology continues to advance, the Alliance will focus on expanding digital access, fostering innovation and addressing the digital gender gap to create a more inclusive digital future.
About the Sustainable Impact Meetings 2024
The Sustainable Development Impact Meetings 2024 are being held this week in New York. Over 1,000 global leaders from diverse sectors and geographies will come together to assess and renew global action around the United Nations Sustainable Development Goals (SDGs) through a series of impact-oriented multistakeholder dialogues. The meetings are an integral part of the Forum’s year-round work on sustainable development and its progress.
And all the media attention gives us a teaching moment to help illuminate the behind-the-scenes dynamics that affect international pharmaceutical markets, insurance companies, public healthcare systems and government finances. This article summarizes the various issues that have been in the spotlight and additional posts linked in the supplemental section at the end of this article will go further behind the curtain, using Ozempic as an example, to explain the interconnected and complex economic factors and government machinery that play roles in determining the supply, demand and accessibility of pharmaceutical treatments and products, as well as broader economic responses.
First, some background.
GLP-1 receptor agonists (like Ozempic) have been used for more than 16 years to treat type 2 diabetes and for weight loss for the past nine years. Ozempic is Novo Nordisk’s brand name for a semaglutide marketed and sold for treating type 2 diabetes. Other medications in the same class include Trulicity (dulaglutide, GLP-1) and Mounjaro (tirzepatide, a dual GLP-1/GIP).
While Ozempic is heavily associated with weight loss in the media, it is NOT approved by the FDA or Health Canada as a weight-loss drug.
From the globex press release: “GlobexPharma® is thrilled to announce the launch of Ozempic Chewable Gummies for Kids®, a groundbreaking prescription treatment designed to combat obesity in children aged 1 to 5 years.”
Health Canada approved it in 2018 for adult patients with type 2 diabetes, noting that there was limited information on safety and efficacy for minors or people over age 75. The FDA has authorized it for similar purposes and also includes reducing the risk of heart attacks and strokes in type 2 diabetes patients with known heart disease.
Wegovy, a similar injectable medication containing higher amounts of semaglutide and made by the same company, is approved for weight loss in obese patients by the FDA and recently entered the Canadian market (it was approved in 2021, but only became available to consumers in May 2024). Saxenda (liraglutide, GLP1), is approved for weight management in obese pediatric patients over 12 years of age in Canada.
The class of medications is not new, their effectiveness for weight loss in non-obese patients, as well as their potential to improve fertility, reduce cardiac risks, and reduce the risk of kidney failure have all increased the attention and discussion of this class of medications.
Their growing weight-loss popularity has disrupted the market, and provides an opportunity to investigate many interrelated market dynamics including:
The incentives and potential for pharmaceutical companies to expand markets for existing products by finding new applications for them.
Similarly, off-label prescribing by physicians can provide patients access to treatments, even if a full-scale clinical trial has not been conducted.
Market expansion through new indications and off-label prescribing can create surges in demand that increase financial risks for public and private drug insurance plans.
Similarly, rapidly increasing demand increases the risk of drug shortages, at least until manufacturing capacity can expand to meet the new market demand.
Both shortages and financial risk for insurance companies can lead to restricting coverage and rationing supplies to prioritize particular patient groups.
The healthcare market and broader economy respond to these dynamics in sometimes unexpected or potentially counterproductive ways. For example, counterfeit or black market versions of the regulated medications, a proliferation of virtual services advertising directly to consumers that they can provide access, and patients failing to complete treatment due to costs or shortages. There is evidence of wider economic responses as well.
For example, Nestlé is launching a new line of frozen pizzas and pastas enriched with protein, iron, and calcium designed for people taking appetite suppressing drugs.
That’s our landscape. For The Silo, Rosalie Wyonch.
About 14 percent of Canadians aged 12 and older – approximately 4.6 million people – did not have a regular health-care provider in 2022, according to Statistics Canada. Even more alarming, about 6.6 million Canadians rely on family doctors aged 65 and over, meaning that even more people could soon find themselves adrift as their physician retires.
Canada has the highest number of general practitioners per capita among comparator countries, yet ranks worst in terms of having a doctor or a regular place for medical care (only 86.2 percent of surveyed Canadians had one in 2023).
What is happening?
Several factors are at play.
First, it’s no secret that the physician workforce, much like the rest of our population, is aging. There aren’t enough new graduates to replace retiring physicians and meet the needs of a growing population. [Canada currently has one of the highest Immigration rates in the world with rates growing steadily and currently sit at around 1.2% population increase each year. CP]
Moreover, physicians have been spending fewer hours on direct patient care. Administrative tasks, such as paperwork for insurance claims, sick notes, and duplicate form requests from different organizations, consume approximately 18.5 million hours of physician time annually in Canada, equivalent to 55.6 million patient visits. Economic and cultural factors are also steering medical trainees towards specialties rather than general family practice. Without changes, the gap between the supply and demand for family physicians will only widen.
My recent C.D. Howe Institute analysis shows that under a normal retirement scenario – where 57 percent of family physicians aged 75 and over retire – the projected supply of family physicians in 2032 will meet 90 percent of the demand. If all family physicians aged 75 and over were to retire, only 78 percent of projected demand would be met, leaving us 13,845 family physicians short.
This means that about 9.6 million Canadians could be without a family physician in the next decade. The consequences of this shortage could be dire, leading to delayed or inadequate care, increased costs, and a strain on other parts of the healthcare system.
With only about 1,550 family physicians completing residency in 2022, the current pipeline of graduates is insufficient. What needs to be done?
Increasing numbers is essential, but will not suffice to meet the demands of a growing and aging population. We need a comprehensive strategy, and five well-established strategies can help.
First, we need to increase the number of training positions for prospective family doctors and accelerate pathways for international medical graduates to enter family medicine, whether direct-to-practice or through residency positions.
Second, administrative processes need to be streamlined to reduce family physicians’ unnecessary workload, freeing more time for direct patient care.
Another strategy is to introduce payment models such as capitation or bundled payments that better support family physicians, making family practice more attractive and encouraging more patient enrolment and after-hours care.
As well, allowing other primary-care providers, such as nurse practitioners and pharmacists, to take on a broader range of responsibilities could assist with sharing the workload and improving patient access.
Finally, developing and expanding team-based models of care that bring together health-care professionals to provide comprehensive and continuous patient care could also benefit Canadians.
The good news is that some of these steps are starting in some provinces.
Nova Scotia is advancing on all fronts; creating a new designated pathway to residency for international medical graduates; committed to reducing physician red tape by 80 percent by 2024; is a leader in paying family physicians with alternate payment; introduced pharmacist-delivered primary care for 31 minor ailments; and expanded team-based care at new and existing locations. Similarly, British Columbia and Ontario have made notable advancements in several of the five strategies.
Improving primary-care access is a nationwide challenge that requires concerted efforts and innovative solutions. By learning from the policies and experiences of different provinces, Canada can develop and implement effective strategies to ensure every Canadian has access to a family physician and the primary care they need. Canada’s health-care system – and the health of its people – depends on it.
For the Silo, Tingting Zhang -Junior Policy Analyst at the C.D. Howe Institute.
The intense debate pitting private versus public healthcare in Canada needs a reality check. Private aspects of healthcare exist in different forms and to varying degrees across Canadian provinces, largely depending on their respective legislation and regulations. For healthcare professionals providing insured services, most bill through the public system, but not all. The current and future scope of their role is the pressing issue at hand.
Health Canada has had success in eliminating extra billing and user fees under sections 18 and 19 of the Canada Health Act. However, provinces have considerable authority in determining key terms like “medically necessary” or “insured services” that are covered under the Act. The result has been a diversity of approaches. Provinces have the legislative tools to constrain the growth of private healthcare, if that is their objective. Similarly, provinces have considerable authority to increase the scope of private healthcare, if that is their objective (even within the current parameters of the CHA), by revising provincial legislation or regulation.
Either way, the specific policy direction undertaken would be different for each jurisdiction, as the legislative and other barriers to private healthcare (such as market size limiting the viability of private delivery) vary across provinces. This Commentary provides clarity about the different forms of “private” healthcare and a comprehensive view of the current policy landscape defining the balance between public and private healthcare.
All health systems incorporate some mix of public and private healthcare. In 2021, public sector spending in Canada amounted to 73 percent of total healthcare expenditure, exactly equivalent to the OECD average of 73 percent (OECD 2023). Yet these summary figures tell us little about the public/private contours of any healthcare system. Private healthcare can manifest in a multitude of ways, and the precise configuration of the relationship between public and private healthcare tells us more about the system than the absolute level of public or private spending.
Under the Canadian Constitution, provinces have wide-ranging jurisdiction over the provision of healthcare in Canada, both explicitly (hospitals) and through judicial interpretation (“matters of a merely local or private nature,” as well as authority over insurance). The Canada Health Act (CHA) does provide a national framework (supported by federal transfer funds) that has, for several decades, ensured a certain level of congruence across provinces in the provision of public healthcare. But each province’s health legislation is unique, and it is this interplay between federal and provincial legislation that provides a regulatory space for private healthcare. Variation across provinces means private healthcare in Canada is not a uniform phenomenon.
The objectives of this Commentary are fourfold: first, to describe the ways we can understand “private” healthcare; second, to explain the different ways provincial legislation permits or prohibits aspects of private healthcare; third, to discuss the supply- and demand-side variables causing private healthcare to take its current shape across provinces; and fourth, to analyze the relationship between provincial healthcare legislation and the CHA with reference to the expansion of private healthcare in Canada. This Commentary does not address the utility of private healthcare per se. Rather, it focuses on the confusion inherent in so many discussions referencing “private healthcare.” Both exponents and critics of private healthcare can pick and choose from numerous manifestations of private healthcare to support their respective positions. By requiring proponents and opponents to clarify precisely what they mean by “private healthcare,” the potential costs and benefits can be more clearly identified in each case.
What do we mean by “Private Healthcare”?
Critics of private healthcare point to the costs and inequities of the American healthcare system to argue against it, while proponents reference European mixed public/private models to show how effective it can be. Any discussion of the role of private healthcare should therefore first clarify what, precisely, is meant by “private healthcare.” Healthcare systems can generally be broken down into three constituent parts: delivery, financing, and regulation. Any of these elements can include a public or private (for-profit or not-for-profit) component (Wendt et al. 2009; Böhm et al. 2013; Marchildon 2022).
Much healthcare in Canada is delivered by private providers. When medicare was introduced in Saskatchewan in 1947, physicians vehemently protested. A settlement was reached only when the province agreed to recognize physicians as private independent operators rather than as employees of the state (Marchildon 2020). This model was followed by other provinces as they introduced their own medicare legislation. Ambulance services across Canada are often private, with these companies negotiating service contracts with health authorities or provinces. Nursing care in hospitals and district nursing programs is generally provided publicly, but private nursing firms (such as the not-for-profit VON for home care, or for-profit firms supplying temporary placements in hospitals) are also commonly utilized.
Historically, hospitals in Canada (especially those founded by religious orders) were largely based on a private, independent, not-for-profit model. As hospitals became amalgamated into health authorities, they were consolidated in provincial governments’ financial statements and their operation was generally subsumed within the public infrastructure – even as many (especially larger) hospitals with boards of directors remain not-for-profit organizations.
What, exactly, is a “not-for-profit” (NFP) organization in Canada, and how does it differ from a private or a public one? Legally, NFPs are “bodies corporate without share capital”: in other words, revenues must be directed to the mission of the organization rather than to shareholders. NFPs also enjoy specific tax breaks. Unlike fully public bodies, however, they are self-governing. Generally, they will have boards of directors who are accountable for funds raised and debts incurred. Like directors in a private company, these directors have a fiduciary responsibility to use resources wisely. Unlike private companies, directors of NFP organizations are directly responsible to the corporate entity rather than to members (i.e., shareholders). The corporate entity, in turn, is responsible to the government jurisdiction (federal or provincial) wherein it is incorporated.
Increased attention has been paid to private surgical companies. Individual medical specialists are generally considered independent private operators who contract their services to medical facilities or universities, although their payment models often include elements such as base salary, research stipend, fee for service, etc. Surgical specialists have in many provinces established discrete private businesses where bulk services (a specific number of certain surgical services) are provided over a set period for a negotiated price (e.g., the Shouldice Hernia Centre in Ontario or Scotia Surgery in Nova Scotia). They may use public infrastructure (hospital operating rooms) or provide their own physical space. There is considerable debate whether contracting these services is superior to establishing them as part of the public system (e.g., Day 2023; Lewis 2022; Longhurst 2023). However, as the funding and administration of these services is controlled by provinces (or provincial health authorities), and as patients use these services as they would fully public services (i.e., free at point of delivery), they are not considered a “two tier” form of access to healthcare. Patients cannot access these services directly; rather, they are routed through the public system. Grey areas of private service delivery, described in more detail below, include the private delivery of medically necessary diagnostic services, infusion clinics on hospital sites, and certain forms of virtual care.
Also relevant to the discussion of private delivery is the type of private entity under consideration. “Private” hospitals that are not-for-profit may in fact operate more like a public institution than a private one; here one might usefully distinguish institutions which are functionally embedded in provincial healthcare system (e.g., via accounting practices) from those that operate at arm’s length. Conversely, evidence from the United States suggests private not-for-profit hospitals can also show the kind of profit-driven behaviour more commonly seen in for-profit entities (Silver-Greenberg and Thomas 2022). Others have argued that small independent private health clinics (such as Algomed or Bluenose, in Canada) are in a different category from large American corporate entities (such as the Hospital Corporation of America) (Deber 2003).
As noted, some privately provided services (such as ambulance services or surgical clinics) are often funded publicly. And, while it is not as common, publicly provided services can be funded privately (e.g., in systems where money follows the patient, private insurers may be able to find places for their patients in publicly funded hospitals). Charitable NFP organizations can be another source of healthcare funding. In Canada, much attention is paid to the division of healthcare into services that are, or are not, insured publicly. For example, the provision of cosmetic surgery (undertaken for aesthetic reasons) is commonly private, and is paid for privately and directly out-of-pocket. The private provision of services that are publicly funded (such as cataract or hip replacement surgery), as noted, is more controversial, but is not uncommon within Canada. The main point of controversy in Canada is whether publicly insured services should also be available for direct purchase to individuals within the private sector, bypassing the public system altogether.
Out-of-pocket financing in Canada is largely targeted to healthcare services that are not covered by public insurance (the precise list of insured versus non-insured services varies across provinces). Only 12.6 percent of Canadian healthcare expenditure in 2021 was comprised of out-of-pocket spending (WHO 2023); the remainder was covered by public or private insurance.
Public insurance: In all provinces, most medically necessary healthcare services are largely funded on a tax-based model, where citizens support healthcare services through their general tax contributions. Some provinces do require provincial inhabitants to pay “healthcare premiums” but, as these contributions simply go into the provinces’ general operating funds, rather than a bespoke account used only for healthcare, these premiums can be considered simply as another form of taxation. As a condition of receiving federal health transfers, the CHA requires that each province has a public insurer. Böhm et al. (2013) argue, for this reason, that states such as Canada and Australia, which are structured on a public insurance system, are more properly considered to possess “national health insurance systems” rather than “national health systems,” as typified by the UK.
Each province has the authority to determine what it insures publicly (which is why coverage for “medically necessary services” varies across provinces). In general, medically necessary services provided by physicians and in hospitals are covered (as required by the CHA) but, as explained below, this is much more complicated than it appears. Services such as vision care and dental care provided in hospitals are also generally covered, as are diagnostics, physiotherapy, and other related services.
Provinces are not required to cover everyone: those in the armed forces or federal penitentiaries, for example, are insured by the Government of Canada. Although provincial healthcare systems provide many of the services for these specific groups, the provinces are reimbursed by the federal government. Those injured in the workplace are usually covered by workers’ compensation. Certain categories of migrants (such as refugees) are also insured federally until they receive permanent citizenship status, whereupon they fall under provincial insurance. Depending on the type of work and the length of stay, migrant workers are insured both through provincial health plans and workers’ compensation programs (for a fuller discussion, see Fierlbeck and Marchildon 2023).
Most provinces expand public health insurance beyond what is required by the CHA. While the CHA does not specifically mandate the public provision of dental care, optometry services, and pharmaceuticals outside of hospitals, provinces generally have some form of coverage of these services for vulnerable groups. These are determined either by cohort (e.g., seniors or children), service (pharmacare or dental care), income category (below a certain ceiling), or some combination of all three. These programs vary considerably across provinces.
Private health insurance: Formally, there are several types of private health insurance, each serving a different function.
Supplementary health insurance covers any goods or services that are not covered by public insurance. In Canada, these include companies like Blue Cross, Sun Life, or Canada Life Assurance. Any healthcare system incorporating public insurance will also have an array of private and private not-for profit supplementary health insurance companies which generally cover vision care, physiotherapy, pharmaceuticals, travel insurance, etc.
Complementary health insurance completes the cost of a service, where public or social insurance only pays partial costs. In many countries, for example, public insurance will only cover around 60 percent – 80 percent of hospital stays, pharmaceuticals, primary care, and sometimes even emergency care. In these cases, private insurance will “top up” the remaining costs so patients do not have to pay out-of-pocket. Some insurers may ask patients to pay the remaining costs up front, and reimburse them after the fact; others may cover the costs at point of payment. This “top up” system is not common in Canada, but in Quebec (which mandates pharmacare insurance) private insurers are allowed to cover any co-pays for pharmaceuticals that patients must pay directly for amounts not covered by the mandated insurers.
Substitutive health insurance applies in systems (e.g., in Germany) where citizens earning above a set income are allowed to opt out of public insurance systems altogether, and use private for-profit insurance to cover medical needs.
Duplicative (or “dual” or “parallel”) health insurance is the source of most political controversy in Canada. Duplicative insurance privately covers services that are also offered in the public sector. Four provinces (Ontario, Manitoba, Alberta, and PEI) explicitly prohibit duplicative insurance, three (Saskatchewan, British Columbia, and Quebec) explicitly permit duplicative insurance under certain conditions (i.e., only for certain services, only if the insurer is private not-for-profit, only for services provided by practitioners outside of the public system), and three (Newfoundland, Nova Scotia, and New Brunswick) neither expressly permit nor prohibit it (Appendix Table A2).1 The advantage for those with duplicative insurance is that they can access these services quicker, or access more enhanced variants of these services. It is really with this particular kind of private insurance that the issue of “two tier” healthcare arises. The argument in favour of duplicative insurance is that it “takes pressure” off of the public system (e.g., Globerman 2020), while other research has found that public wait times actually increase when publicly insured services become privately available. One reason given for this is the depletion of resources from the public sector. Policy analysts also suggest that those offering private services have incentives to keep public wait times longer, as patients will only find private services attractive if they cannot easily access them in the public sector (e.g., Besley et al. 1998; Duckett 2005). Countries such as the UK that permit duplicative insurance nonetheless continue to have considerable issues with long wait lists in the public health system (e.g., Duncan et al. 2023).
Private not-for-profit insurance: Another category of health insurance that causes much confusion is statutory health insurance (SHI; also referred to as “social health insurance” or the “Bismarck health system”). This system is quite common in Europe, although the precise configuration varies across states. In this model, health insurance is not covered in the first instance through general taxation revenue. Rather, workers and employers pay into “sickness funds,” which provide health insurance benefits depending on the terms negotiated. These sickness funds are technically “private” bodies operating on a not-for-profit basis. They are, however, highly regulated in their authority and function. Because of the degree of regulation – and the importance of the social function they fulfill – they are generally considered a form of “public” insurance. However, governments tend to differ in their approach to consolidating these operations into government expenditures.2 Jurisdictions using this model of health insurance have different methods for covering unemployed or retired persons, often including funds directed from government taxation revenue or from pooled sickness funds.
The nature of “private” healthcare is determined not only according to the way services are delivered or funded but, more importantly, according to the way they are regulated. Permitting a “private” form of health service or insurance is not an all-or-nothing condition; governments have the authority to determine the terms and conditions under which these services are to be offered. There can, for example, be limitations on the kinds of services offered or insured, on the professions allowed to offer them, on the prices that can be set for them, where they can be provided, and so on. These limits, as discussed below, can be enough to discourage the provision of health services even when these services are technically legal, as the terms within which private services are allowed may not be sufficiently profitable. In the European Union (EU), governments are more restricted in their ability to regulate private healthcare services because, ultimately, the ethos of the EU is to maintain the free movement of goods and services. Fully public health services are under the authority of member states but, where states utilize private components in their healthcare systems, attempts to limit the ability of private health firms to compete can result in charges of breaching fair-competition regulations. In Canada, however, there are fewer restrictions on the limits that provinces can place on private health providers, given the political will to do so. The regulatory aspects of healthcare financing and delivery will be addressed in more detail in the next section.
Another category of “private” healthcare is the implementation of private-public partnerships (P3s) in healthcare (McKee et al. 2006). In the past, this has been limited to large capital projects, such as the construction of hospitals, but more recently the implementation of P3s has expanded to the point where verdicts on their effectiveness can be rendered. Importantly, there is no single model of public-private partnerships; each is generally negotiated on its own terms. Proponents explain the logic of this approach as capturing the advantages of both systems: governments can access more competitive financing for projects, while firms undertake the process of construction more efficiently with each day of overrun increasing the cost of a project. Critics argue that the logic of P3s rests in the effectiveness of offloading costs to the other partner, and that the party with the most expertise in negotiating P3 contracts (generally large multinational firms with experience in this area) are those who are most able to shift costs. At the same time, because P3 projects allow costs to be diffused over a long period of time, budget-conscious governments have been eager to enter into these agreements.
Empirical evidence suggests that the effectiveness of P3 projects in Canada has been quite varied (Murphy 2008; Vining and Boardman 2008; Siemiatycki 2015). More recently, provinces have expanded the use of P3s to include large outlays for medical infrastructure. These agreements, often known as “value partnerships” or “managed equipment service agreements,” generally focus on diagnostic equipment – providing MRIs, CT scans, and X-rays – and they range from 15 to 30 years. The private partner will source, install, and maintain this equipment over the life of the agreement. As the private partner owns the equipment and covers the cost of installation, there are minimal upfront costs for the public partner. Other advantages of this model include a reduction in equipment downtime, decreased administrative burden in monitoring equipment maintenance, protection from unpredictable costs involved in equipment failure (CADTH 2022), and a replacement plan for equipment that reaches the end of its recommended useful life. At the same time, long-term service contracts can diminish flexibility in accessing different equipment over the lifespan of the contract, and the private contractor may demand confidentiality agreements which could diminish the transparency and accountability of the process. Like other forms of P3s, the effectiveness of managed equipment services will largely depend on the specifics of negotiated agreements, including clearly defined outcomes and expectations, as well as transparent and accountable protocols and public scrutiny of this documentation (CADTH 2022).
While “internal markets” are not formally an aspect of private healthcare per se, they frequently arise in discussions of the utility of private healthcare mechanisms in the reform of public healthcare. Most famously employed in the Thatcherite reforms of the National Health Service in the United Kingdom, this model simply divides public healthcare professionals into “purchasers” of acute care services (usually primary care professionals) and “providers” of acute care services (usually hospitals). The theory underlying the purchase-provider split is that GPs will select the best value for money, obliging hospitals to compete by offering quality services for less. While the results of Britain’s experiment with the internal market are mixed at best (for a discussion of the internal market reforms see, e.g., LeGrand, Mays, and Mulligan 1998; and Ham 2007), a number of other countries (such as the Netherlands) have since incorporated this mechanism into their own healthcare systems.
Conclusions
The nature and extent of private healthcare provision has always been a subcurrent in discussions of Canadian healthcare. As Flood and Archibald clearly demonstrated in 2001, however, the precise nature of private healthcare depends upon the structure of provincial legislation. In general, provinces with a critical mass of population and wealth had to be more actively restrictive in their policy instruments regarding private healthcare, with smaller provinces able to enjoy a more liberal legal framework safe in the knowledge that low demand would make the opportunity immaterial. While legal frameworks are generally holding firm, the practice and context of healthcare provision have been changing rapidly. Both supply and demand pressures are making private healthcare more available and more attractive to those requiring healthcare.
This Commentary has not discussed the provision of duplicative private health insurance in Canada. The experience of post-Chaoulli Quebec has shown that the demand for duplicative insurance is still limited given the current policy framework (see Quesnel-Vallée et al. 2020). Nonetheless, if private service provision becomes widespread, and the demand remains constant (or increases), provinces that permit private insurance (but have not experienced demand) may well see its tentative development within their jurisdictions, while provinces where duplicative insurance is proscribed may experience greater political pressure to allow it.
Laverdière (2023) has argued that a “plausible interpretation” of the CHA is that “transfer reductions can only occur when the public system in a province or territory does not provide satisfactory access to medically necessary services.” This is not an incorrect observation per se; it merely confuses the legal and political aspects of the CHA. Whether provinces have met the contractual conditions to expect the funds set out by Ottawa is a largely technical matter. The success that Health Canada has had in eliminating extra billing and user fees under sections 18 and 19 is illustrative of the utility of a clear and specific set of requirements that are monitored and enforced (with the added incentive that provinces can recoup any past losses if they make prospective changes). More complicated are the charges that provinces have been non-compliant with the CHA beyond sections 18 and 19. Because provinces have considerable authority in determining key terms like “medically necessary” or “insured services,” it is difficult to make justiciable claims against provinces for non-compliance more broadly. The contest over diagnostic services and virtual care will be an interesting one. But the terms of the dispute are more political than legal. As in the past, the federal government is using the CHA as a political statement to affirm its commitment to public healthcare; as such, the legal outcome of the controversy may be less important than the political battle.
Is the CHA obsolete? The demand that the CHA should be revised, either to prevent or facilitate private healthcare, is misplaced. The instruments determining the extent of private healthcare largely rest, as they always have, with the provinces and the political will of their electorates. In the past, the best barrier to privatization has been an effective and responsive public system. For this reason Ottawa’s role in funding provincial healthcare remains paramount. Provinces have the legislative tools to constrain the growth of private healthcare, if that is their objective. Similarly, provinces have considerable authority to increase the scope of private healthcare, if that is their objective (even within the current parameters of the CHA), by revising provincial legislation or regulation.
Either way, the specific policy direction undertaken would be different for each jurisdiction, as legislation and other barriers to private healthcare (such as market size) vary across provinces. For example, should Ontario wish to expand the private provision of healthcare, it could simply rescind sections 15(a) of the Ontario Health Insurance Act and section 10(3) of the Commitment to the Future of Medicare Act (along with the corresponding regulations). To expand the scope of private healthcare, the nine provinces that already allow physicians to opt out of the public insurance system have a number of mechanisms at their disposal. These include permitting physicians to charge above the current fee schedule where that is now explicitly prohibited, reimbursing patients who use private-sector physicians where they do not already do so, or permitting “dual” or “duplicative” insurance where it is currently prohibited. The greatest effect would be in the wealthier and more populous provinces where a critical mass of individuals who would be willing to pay to access these services would make private healthcare a viable commercial venture. The scope for expanding private healthcare in smaller provinces is more restricted, but still could be facilitated by, for example, allowing physicians to bill above the public fee schedule.
Similarly, provinces can use legislative mechanisms at their disposal to further restrict the expansion of private healthcare by, for example, refusing to reimburse patients who have paid physicians directly for services listed as “insured services” (as some already do). Doing so could also potentially expand private healthcare by increasing the number of non-participating physicians (who are outside the purview of the CHA). However, this could in turn be addressed by restricting the fee schedule of non-participating physicians or, like Saskatchewan, by permitting liberal private care only up to the point that it is deemed to undermine public care. Moreover, simply by changing the definition of “insured services” from “medically required services provided by physicians” to “medically required services provided by physicians and nurse practitioners” (which can in some jurisdictions be done through orders-in-council alone), some provinces could forestall the expansion of private nurse-practitioner-run clinics. Provinces can also control the precise scope and nature of additional private healthcare services by tightly regulating the specific terms under which these services are permitted. Quebec, for example, has for years allowed private health insurance only for specific procedures; Saskatchewan permits private health insurance, but only if offered by non-profit entities. Privatization, in this way, does not necessarily entail a “wild west” of unrestricted commercial ventures. At the same time, provinces that pursue this route will also have to commit considerable resources for monitoring and ensuring compliance (where currently most provinces simply utilize a complaint-driven system).
Canada’s unique federal system means that fears of privatization can also be useful in leveraging more funding from Ottawa. Rather paradoxically, provinces have an incentive not to contain the growth of private healthcare within their borders in order to make the case that more public funding is necessary. At the same time, Ottawa has agency with regard to going beyond the mandated provisions of sections 18 and 19. It could demand provinces cleave to the spirit of the CHA by publicly insuring services regardless of whether they are provided in the way they were when medicare was first conceived. Ultimately, however, governments are responsive to their electorates. The legal intricacies that exist in the nexus of provincial legislation and the CHA will always remain secondary to the wider political opposition to, or support for, private healthcare. To engage in this political debate, however, it is important to understand clearly what private healthcare is and is not, and how it manifests within the legislative landscape of each jurisdiction. For the Silo, Katherine Fierlbeck.
Dr. Fierlbeck is cross-appointed to the Department of Community Health and Epidemiology, the Department of International Development Studies, and the European Studies Program at Dalhousie University. She is a Senior Research Fellow at the Healthy Populations Institute, and is on the research committee for the MacEachen Institute for Public Policy.
As a Black man and a spiritual leader in the Linden community, I am concerned and am a personal victim about the disproportionate impact of prostate cancer on Black men. It is unacceptable that Black men are about twice as likely to get and die from prostate cancer than white men. While we still do not know definitively why this is the case, there are several factors that contribute to this reality.
Genetics may play a role. Studies have shown that prostate cancer in Black men has a different genetic profile, and it is a more aggressive form of the cancer. Additionally, Black men are underrepresented in clinical trials, which limits our ability to understand the disease’s impact and identify effective treatments. Lack of access to healthcare and inconsistent screening programs also contribute to the higher mortality rates among Black men.
But it’s not just genetics or lack of representation in clinical trials that cause this disparity. The cost of care, limited access to quality healthcare, and systemic racism create a barrier to care and early detection. Add to that the economic challenges faced by many Black men, such as the cost of cancer care and the inability to take time off work to recover from treatment, and it’s clear there is a multi-layered issue that must be addressed.
We cannot afford to remain silent on this issue. We must educate ourselves and our communities on prostate cancer risks and symptoms and the importance of timely screening. We must push for universal access to healthcare and encourage participation in clinical trials. And we must work to break down systemic barriers and create an equitable system of cancer care for all, regardless of race or ethnicity.
As a cancer patient myself, I understand how harrowing a prostate cancer diagnosis can be. However, it’s essential not to let the diagnosis define you and have faith that you can overcome any obstacle. Supporting each other and bringing awareness to life-saving prostate cancer screening is critical to reducing the disparities faced by Black men with prostate cancer. For the Silo, Imam Alfred
Imam Alfred Muhammed is working within the African American community on issues of leadership, peace, and interfaith outreach. Imam Alfred has inspired inner-city youth to self-actualization, promoted healthy family relationships, and improved economic development in the Linden community. He is now fighting stage 4A prostate cancer and has been forced to limit his engagements while spending more than $70,000 usd on alternative healthy treatments.
Before his conversion to Islam the Imam Alfred Muhammad was raised as a Christian in rural Virginia. His journey in religious leadership began in childhood as a Baptist preacher, but in 1960 the young minister Muhammad converted to the Nation of Islam. While in the NOI his desire was driven to become active in the 1960s Civil Rights Movement. Most notably, the Imam managed voter registration drives and worked closely with the lieutenants of Dr. Martin Luther King, Jr.
Have you ever felt like you need an upgrade on your life?
Most of us have – and there’s a way to get it, says veteran physician Sanjay Jain.
“First, I tell people, ‘Don’t be afraid of making your life clearer.’ but as we have paraphrased from Chinese philosopher Laozi, ‘The journey of a thousand miles begins with the first step,’ ”. Many argue that life is not simple and, therefore, there are no easy answers, says Jain, whose specialties include integrative medicine. He’s also an international speaker and author of Optimal Living 360 – (www.sanjayjainmd.com).
“Lives are built from many small components which, when viewed as an assembled whole, can appear overwhelmingly complex,” Jain says.
“But when we break them down and consider the pieces as we make decisions in our lives, it’s much easier to see how small adjustments can result in a better return on all of the investments we make – not only in health, but in relationships, finances, and all the other essential aspects of our lives.”
Jain offers four points to keep in mind as you start the journey.
• Life is short, so live it to its fullest potential. Live it optimally. This is your life, so don’t waste its most precious resource – time. No matter one’s spiritual leanings, economic and education status, health, intelligence level, etc. – one thing is true for all: Our time on Earth is finite. There will be a time for most of us when, perhaps after a frightening diagnosis from a doctor, we reflect deeply upon our time and consider the most important moments, and all the time that may have been squandered.
• Balance is key. Too much or too little of something, no matter how good, is actually not good. Balance is one of the easiest tenets to understand, but arguably the most difficult to maintain. Obviously, too much alcohol is bad; then again, there are some health benefits to moderately imbibing red wine. What about too much of a good thing; can a mother love her children too much? Yes, if she is an overprotective “helicopter parent.” The best antidote to overkill of anything is awareness; try to be aware of all measures in your life.
• Learn to tap your strengths and improve upon your weaknesses. Engaging your strengths at work and in your personal life is important. When we do what we’re good at and what comes easily, we feel self-confident and satisfied. Some people, however, are not in jobs that utilize their strengths, or they don’t put their talents to work at home because they’re mired in the prosaic work of living. It’s important to identify your strengths and find ways to engage them. It’s equally important to recognize our weaknesses and work on improving them (because we can!) This is essential for achieving balance.
• Life is about making the right choices. Integrative decision-making makes this easier. There are many different types of decision-making, including systematic, hierarchal, impulsive, decisive and flexible. Integrative decision-making can be used for problems large and small, and includes the following process: 1. Define the problem. 2. Frame the problem. 3. Develop all your options. 4. Analyze your options. 5. Make the decision. 6. Execute your decision. 7. Debrief yourself.
While experts may be the best consultants for compartmentalized areas of your life, only you know the other aspects that affect your well-being and can determine how a decision in one area will affect another area. For the Silo, Ginny Grimsley
Only 10% of rare diseases have an FDA-approved therapy. This sobering statistic highlights why research is so imperative for patients with rare diseases. Clinical trials can be a crucial opportunity to access life-saving treatments.
However, African-American, African-Canadian and Latino patients with rare diseases face significant underrepresentation in clinical trials. This lack of representation results in drugs being developed that aren’t proven safe or effective across different populations.
A 2018 research carried out by the U.S. Census Bureau stated that out of the 12% Black or African American population across the U.S., only 2.2% had participated in clinical trials for rare diseases. Sickle cell disease is one rare disease that predominantly affects the African American community.
India has close to 50-100 million people affected by rare diseases or disorders, with almost 80% of these rare condition patients being children. As per the U.S. Census Bureau, Indian Americans constitute 1.2% of the U.S. population, which translates to 4.5 million, as of 2021, and out of the 5.8% total Asian population across the U.S., their clinical trials participation in 2018 was only 1%.
When certain groups are underrepresented, the universal right to health is jeopardized, and the economic burden of public health care rises. Inequities in clinical research participation impede applications in drug efficacy, toxicity, therapeutic indices, and other areas. Furthermore, it has the potential to raise healthcare costs.
February is “Rare Disease Month”, while February 28th is “Rare Disease Day”, and 2023 is the 40th anniversary of “The Orphan Drug Act”—a law that was passed in the United States in 1983 to facilitate the development of orphan drugs—drugs for rare diseases.
Dr. Rajasimha, Founder and Executive Chairman of IndoUSrare says, “Rare Disease Month allows the rare disease community to come together and make themselves heard.”
The future of rare disease research and treatment still requires enhanced detection techniques, dissemination of understanding concerning optimal care, and research to prevent, treat, and cure disease, and IndoUSrare collaborates with researchers in the U.S. and other western countries with their counterparts in the Indian subcontinent to engage and include the large and diverse populations of Indians in India and globally.
A study by Compare the Market Australia has analyzed each country around the world on their annual search volume for terms such as ‘relocating to [country]’ and ‘moving to [country]’ to reveal the world’s most desirable countries to relocate to.
The most desired countries to relocate to? Here comes a boring chart!
Rank
Top destination
Favourite in X countries
1
Canada
50
2
Japan
31
3
Spain
19
4
China
15
5
France
11
6
Turkey
9
6
South Africa
9
8
India
7
9
Australia
6
10
Greece
4
10
Fiji
4
Taking the top spot is Canada, with our North American nation being the most desired destination in 50 other countries around the world. Canada is a very welcoming country for expats, which has led to it becoming a very diverse and multicultural destination.
Second place goes to Japan, with 31 countries having it as their number one relocation destination, including Australia. Japan has one of the highest life expectancies in the world, which could explain why so many people are researching to move there.
Spain is another very popular choice, especially amongst those in other European countries, with 19 countries having it as their favourite in total. Known for its warm Mediterranean climate, Spain is also another destination that has excellent healthcare and quality of life.
The least desired countries to relocate to in the world include: Sweden, The Philippines, Bulgaria, Germany, Thailand, Egypt, Singapore, Myanmar, Italy, and Nigeria with only one other country wanting to move to each of these destinations.
Further Study Insights:
Each country’s most desired relocation destination
Check the map below to see where each country in the world wants to relocate to the most.
While the majority seem to prefer somewhere within the same continent, there are some notable exceptions to this.
As the most searched country overall, we can see that people from as far away as India and South Africa have Canada as their most searched destination.
However, there were also some definite regional trends though. For example, many African nations have South Africa as their most searched destination.
Methodology
Using Google Ads Keyword Planner, the annual search volume for each of the following terms was found for each country in the world:
Houses in [country]
[Country] property
Moving to [country]
Relocating to [country]
This process was then repeated for each country in the world, taking a total of the searches across all four search terms, to reveal where each country wants to relocate to the most.
Note that searches within the same country were removed from the results.
In addition, all searches were carried out in English, as results in native languages proved to give inconsistent results.
What do you do when Western medicine fails to heal what ails you?
Mitzi Mensch knows only too well what happens once doctors have exhausted their bag of tricks. Through her writing, Mensch hopes to raise awareness of the dangers of Aspartame, challenge doctors to find answers – not simply mask symptoms – and to bring out the hopeless romantic in her readers.
Healthcare has turned into a multi-trillion dollar industry as patients around the globe are herded into doctor’s offices, only to leave with prescriptions in-hand for brightly colored pills. But what happens when the pills don’t work and the doctor is out of ideas of how to treat your symptoms? Mitzi Mensch knows first-hand the challenges this presents and has written about her experience in The Dangers of Kissing and Diet Coke: What Your Doctor Doesn’t Know and Won’t Bother to Find Out, a neurological nightmare juxtaposed with a riveting love story.
This medical mystery has Mitzi playing dual roles of patient and detective all while embroiled in an intense affair with her long lost first love.
There was the “Go to Psych” doctor, the “We’re out of time doctor”, the “No, next” doctor. Physicians pushed pills which turned her into an emotional zombie and didn’t work. Alternative practitioners practiced protocols and provided potions which didn’t work. As Mitzi muddled through the morass she searched for anything that claimed to cure pain, calm nerves, create somnolence.
Still her headache raged on, her tics escalated, she didn’t sleep.
Mitzi was determined to find out what was wrong and fix it. And then there is the power of first love, potent and compelling. The Internet has made it so very easy for people separated by years and distance to rekindle what was long ago left smoldering. But should they? Much more than a self-help book, The Dangers of Kissing and Diet Coke sizzles, allowing the reader to voyeuristically experience an affair from the perspective of the ‘other woman.’
Mensch would like to help people through her writing. “Even if one person’s health is saved by eliminating Aspartame, or one person is cured of constant headache, or one doctor will look beyond the obvious – my words will have meant something. One thing I would like for readers to take away from this book is to be your own advocate when you get sick. As for lovers who love down through the decades, sometimes it works. They are the lucky ones. ”
Mitzi Mensch was born and raised in New England and attended college in Vermont. An island girl at heart, she lives in Hawaii. Available on Amazon.com, AuthorHouse.com and local bookstores. The Dangers of Kissing and Diet Coke: What Your Doctor Doesn’t Know and Won’t Bother to Find Out By Mitzi Mensch Publisher: AuthorHouse ISBN-13: 978-1491814147
Pasadena, Calif. (November, 2020) – Innova Medical Group, Inc. (IMG) has partnered with the UK Government in its roll out of whole city screening and testing, beginning in Liverpool, with its INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test Kits.
Innova Medical’s lateral flow antigen test uses nasal and throat swab samples to screen for infection, with highly accurate results in as little as 15-minutes. This test can be easily and safely administered anywhere, on both asymptomatic and symptomatic people, without costly delays and the need for a full-scale laboratory. With its low cost per test, about the same as a coffee and biscuit in London, at-risk populations and many with inequitable access to healthcare, can achieve peace-of-mind with a negative result. U.K. Government data showed the IMG rapid SARS-CoV-2 antigen test screened asymptomatic individuals with 98.98 percent accuracy.
Dr. Susan Hopkins, Incident Director at Public Health England, said, “The tests we are using in Liverpool are accurate, especially in finding people who are infectious at that moment in time and so are more likely to pass it on to others. Part of the purpose of working with Liverpool to roll out whole city testing is to better understand how these tests work in the field, improve understanding of why people get tested, and the impact of this approach on reducing the transmission rate.”
Using the National Health Service (NHS COVID-19) app, people can book a test and later input their test results.
Individuals taking part in the roll out of Operation Moonshot will be notified of positive or negative results by text or email. With this important test-and-trace system in place, public health authorities can diagnose cases, isolate infected patients, trace their contacts, and implement stringent infection control policies to reduce outbreaks.
With colder months and the holiday season ahead, the risk of virus transmission accelerates with more indoor gatherings and travel. If people do not know they have COVID-19, it is unlikely they will take precautions to prevent virus spread. Research studies show that to achieve disease control both asymptomatic, people who are infected but never develop symptoms, and pre-symptomatic, infected people who develop symptoms later, must be isolated.
Under Operation Moonshot, the UK Government hopes to flatten the curve by employing proactive, rather than reactive, measures in its COVID-19 response. Up to 1-in-5 United Kingdom coronavirus infections present with no symptoms, but they are still contagious. The Centers for Disease Control and Prevention (CDC) says up to 40 percent of infected people are asymptomatic and should be tested if they have been exposed. Typically, a person develops symptoms 5 days after being infected; however, infectivity was found to be highest a day before symptom onset. After symptoms, such as a cough, fever, and shortness of breath, first appear, a person can remain contagious for at least ten days.
The Innova Rapid Antigen Test quickly identifies infectiousness. The lateral flow test can identify people with a high viral load who are the most likely to spread the virus. Daniel Elliott, President of Innova Medical Group, Inc., said, “Our lateral flow device incorporates a German nitrocellulose membrane partially composed of nanoparticles of colloidal gold. [ Colloidal gold is nanoparticles of gold in a liquid solution. These gold nanoparticles are coated in such a way that they detect Covid antibodies. CP ] This advanced, proprietary technology combined with our room temperature reagent, allows testing at point-of-care settings such as workplaces, universities, and airports.”
GLOBAL SUPPLY CHAIN AND PRODUCTION
Innova Medical Group Inc. offers a global supply chain including the innovative and respected firms, GE Healthcare (USA) and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. By the end of November 2020, IMG will produce millions of kits per day in its Brea, California plant, combined with activity from plants in other global locations. After being selected over a large number of submissions to take part in Operation Moonshot, IMG is also exploring options for production in the United Kingdom.
The Innova test carries a CE Marking indicating that this IVD device complies with the European In-Vitro Diagnostic Devices Directive (98/79/EC). This device may be legally commercialized in the European Union (EU). For the Silo, Julie R. Manley.
About Innova Medical Group
Innova Medical Group, Inc. (IMG), is a wholly-owned subsidiary of Pasaca Capital (Pasadena, Calif.). IMG strategically pivoted and leveraged its expertise in Healthcare and Medical Devices to create an ecosystem to respond to the COVID-19 pandemic. The Innova Medical Ecosystem is delivering millions of tests every day to satisfy the diverse, point-of-care requirements of the world’s governments, large corporations, and institutions. IMG offers a global supply chain including the innovative and respected firms, GE Healthcare (USA), and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. For more information, visit www.innovamedgroup.com.
As parts of the globe cautiously begin to open up, the focus is on what travel freedom and global mobility will look like in a post–Covid-19 world. Last week the EU released a list of countries whose residents would be allowed entry into the bloc from 1 July based on coronavirus-related health and safety criteria. Included on the welcome list are countries such as Australia, Canada, Japan, and South Korea that traditionally score highly on the Henley Passport Index — the original ranking of all the world’s passports according to the number of destinations their holders can access without a prior visa. However, in a move perceived as a stinging rebuke for its poor handling of the pandemic, the US was notably excluded from the list, as were Brazil and Russia.
Although not reflected in the latest ranking, which does not take temporary travel bans into account, it is eye-opening to consider what travel freedom currently looks like for the holders of once-prestigious passports. For instance, before Covid-19 the US passport usually ranked within the top 10 on the Henley Passport Index in 6th or 7th place, with its citizens able to access 185 destinations around the world without requiring a visa in advance. However, under the current EU ban, the picture looks starkly different. US nationals now have roughly the same level of travel freedom as citizens of Uruguay (included on the EU’s list of welcome countries), which ranks 28th on the index, with a visa-free/visa-on-arrival score of 153. In another striking inversion, the US’s dramatic decline in passport power means that Americans find themselves with a similar level of travel freedom usually available to citizens of Mexico (25th on the index, with a score of 159), current travel bans notwithstanding, albeit temporarily.
This is one of many extraordinary shifts in passport power caused by the temporary pandemic-related bans. Brazilian passport holders, for example, find their passport strength greatly diminished. The country usually ranks highly on the index ¾ most recently placed 19th, with a visa-free/visa-on-arrival score of 170 ¾ but the loss of access to the EU means Brazilians currently have roughly the same extent of travel freedom as citizens of Paraguay (36th on the index, with a score of 142).
Without taking the various travel bans and restrictions into account, Japan continues to hold the number one spot on the Henley Passport Index with a score of 191. Singapore remains in 2nd place with a score of 190, while Germany and South Korea are in joint-3rd place, each with a score of 189. Both Japan and South Korea have been included on the EU’s list of ‘safe’ countries, while Singapore has been excluded, which means Singaporean passport holders currently have far less travel freedom than their closest competitors on the index, which is based on exclusive data from the International Air Transport Association (IATA).
Dr. Christian H. Kaelin, Chairman of investment migration firm Henley & Partners and the inventor of the passport index concept, says the EU’s recent decision will have far reaching effects. “As we have already seen, the pandemic’s impact on travel freedom has been more drastic and long lasting than initially anticipated. This latest decision by the EU indicates that there is more upheaval to come. Look at the US passport, for example ¾ in 2014, it held the number one spot in the world on our index, but US nationals currently have far less travel freedom than most citizens of other wealthy, industrialized nations and even of some less developed nations, being effectively locked out of Europe. We see an emergence of a new global hierarchy in terms of mobility, with countries that have effectively managed the pandemic taking the lead, and countries that have handled it poorly falling behind.”
Immigration controls in US and UK tighten amid calls for co-operation
While the US looks set to be significantly affected by the EU’s latest decision, it has issued stringent immigration controls of its own over the past few months. Greg Lindsay, Director of Applied Research at NewCities, says that the Trump administration’s temporary suspension of all work visas will have far-reaching effects. “The executive order, signed on the 22 June, will bar as many as 525,000 foreign workers from entering the country for the rest of the year.” As Lindsay points out, this decision is only the latest salvo in White House aide Stephen Miller’s years-long campaign to curtail worker visas, arguing that they harm employment prospects for Americans.
In the UK, the pandemic’s effect on mobility has also been severe. Robert McNeil, Deputy Director of the Migration Observatory at the University of Oxford, says that the almost complete cessation of international arrivals into the country has generated serious challenges for industries that have become dependent on seasonal migrant workers from the EU. McNeil says that despite public attitudes around immigration softening, the Brexit process has not slowed down. “In May, the government pushed through the new Immigration Bill, paving the way for a new ‘points-based’ immigration system. The new restrictions would prevent many people from becoming key workers in the UK in future. Around half of the EU citizens currently in key worker positions in the UK would not meet the new salary and skills thresholds required to move to the country from 2021.”
Changing priorities in a transformed world
As premium passports lose their shine in a post-Covid world, experts suggest that the crisis is likely to make international mobility more restricted and unpredictable in the longer term. “Even as countries open their borders, it is expected that numerous governments will use epidemiological concerns as a justification for imposing new immigration restrictions and nationality-targeted travel bans that will mainly be aimed at citizens of developing countries,” says Prof. Dr. Yossi Harpaz, Assistant Professor of Sociology at Tel Aviv University. Noting the recent decision by the EU with respect to the US and other countries, Harpaz says, “The passports of both developing and developed nations stand to decrease in value, at least temporarily. In such uncertain times, global demand for dual citizenship and investor visas is expected to increase.”
Discussing the impact of the pandemic on global migration trends, Charles Phillips, researcher and consultant for Oxford Business Group, suggests that environmental health concerns could become a priority for those seeking alternative residence or citizenship. “We can expect places that are governed well and better equipped to deal with pandemics to become destinations people will seek to move to. Just as travel choices will likely be more strongly influenced by health considerations, we may see those acquiring alternative residence or citizenship placing a greater emphasis on a country’s health policies when deciding where to reside.”
Dr. Juerg Steffen, CEO of Henley & Partners, says the growing demand for additional residence and citizenship options comes as no surprise. “We have seen extraordinary upheaval over the past few months, with many certainties falling away. For investors and their families, having a second citizenship or an alternative residence is an even more precious asset than ever before, as concerns over access to first-rate healthcare, global mobility, and quality of life take on a new urgency. In turn, investment migration programs provide invaluable economic security to the countries that offer them.
As we enter the worst recession since the Great Depression, a small country like Montenegro, for instance, is better equipped to weather the storm. The recently launched Montenegro Citizenship-by-Investment Program provides permanent access and the right to stay in this beautiful and safe European country. It also provides the country with an immediate liquidity injection of much needed debt-free foreign capital that can be used to buffer the impact of the pandemic and create significant societal value.” For the Silo, Sarah Nicklin.
About the 2020 Henley Passport Index
Boasting cutting-edge expert commentary and historical data spanning 15 years, the Henley Passport Index is the original ranking of all the world’s passports according to the number of destinations their holders can access without a prior visa. The ranking is based on exclusive data from the International Air Transport Association (IATA), which maintains the world’s largest and most accurate database of travel information, and it is enhanced by extensive, ongoing research by the Henley & Partners Research Department. Along with the Kälin – Kochenov Quality of Nationality Index, it is considered a major reference tool for global citizens and the standard reference for governments in this field.
Tokyo edges Singapore (2nd) and Osaka (3rd) again to take the top spot globally in 2019.Two North American cities make up the top ten, including Toronto (6th) and Washington, DC, (7th).The remaining top ten cities are: Amsterdam (4th), Sydney (5th), Copenhagen and Seoul (tied 8th) and Melbourne (10th).The 2019 edition of the index includes ten new indicators, of which eight are related to environmental resilience.
The Economist Intelligence Unit today releases the third edition of the Safe Cities Index (SCI) at the Safe Cities Summit in Singapore. The index, which is the centre piece of a research project sponsored by NEC Corporation, ranks 60 cities worldwide across five continents. It measures the multifaceted nature of urban safety, with indicators organised across four pillars: digital, infrastructure, health and personal security.
Cities in the Asia-Pacific (APAC) region make up six of the top ten safest cities, with Tokyo taking the top spot for the third time in a row. Along with Tokyo, other APAC cities, as in the past, dominate the SCI2019. Singapore and Osaka come second and third, while Sydney and Melbourne also make the top ten.
Toronto and Washington, DC, are the highest ranked North American cities in the SCI2019, with Washington, DC, entering the top ten for the first time. Overall, North American cities perform well in digital security, accounting for seven of the top ten cities in this category. These cities include Chicago, Washington, DC, Los Angeles, San Francisco, Dallas, New York and Toronto.
Vaibhav Sahgal, consultant at The Economist Intelligence Unit, says: “US cities continue to perform well in digital security as the government strengthens its cyber-security regulations, while Canadian cities tend to fare better than their US counterparts in personal security. None of the cities in the US make it into the top 20 in the personal security category—Washington, DC, only ranks 23rd, together with Shanghai.”
The SCI2019 benefits from a major revision designed to better capture “urban resilience”—the ability of cities to absorb and bounce back from shocks—a concept that has had an increasing influence on thinking in urban safety over the last decade, especially as policymakers worry about the implications of climate change. The 2019 edition is the third, following the 2015 and 2017 iterations.The SCI2019 scores are not evenly spread, with a large number of cities clustered at the top, and the rest showing wider variation in scores. Just ten points separate the overall scores of the top 24 cities, while the following 36 are 40 points apart. The research shows that levels of transparency in cities correlate as closely as income with index scores.
Research shows that the performance of different safety pillars correlates very closely with each other, signifying that different kinds of safety are thoroughly intertwined. The top performers in each pillar are as follows: Digital security: Tokyo (1), Singapore (2), Chicago (3), Washington, DC, (4), Los Angeles/San Francisco (5)Health security: Osaka (1), Tokyo (2), Seoul (3), Amsterdam (4), Stockholm (5)Infrastructure security: Singapore (1), Osaka (2), Barcelona (3), Tokyo (4), Madrid (5)Personal security: Singapore (1), Copenhagen (2), Hong Kong (3), Tokyo (4), Wellington (5) The leading cities got the basics right, including easy access to high-quality healthcare, dedicated cyber-security teams, community-based police patrolling and/or disaster continuity planning. The accompanying SCI2019 report explores the index results, incorporating 14 in-depth interviews with industry experts around urban safety.
Naka Kondo, senior editor at The Economist Intelligence Unit, and editor of the SCI2019 report says: “Overall, while wealth is among the most important determinants of safety, the levels of transparency—and governance—correlate as closely as income with index scores. Our research shows the many ways that transparency and accountability are essential in every pillar of urban security, from building safer bridges to developing the trust needed for relevant stakeholders to share information on cyber-attacks. The research also highlights how different types of safety are thoroughly intertwined—that it is rare to find a city with very good results in one safety pillar and lagging in others. Policies, service planning and provision should also take this into account—and this year, we have decided to convene stakeholders from around the world in a Safe Cities Summit to discuss such matters around urban safety.”
Presently and in the not too distant future, virtual reality in healthcare will become the norm. In this piece, we’ll show you how VR can help detect, treat and cure patients in all sorts of different sectors, such as Surgery and Dentistry, as well as teaching the Nurses of the future.
VR will also be used to help the development of people suffering from mental disabilities such as Autism and help cure phobias and tend to soldiers dealing with Post Traumatic Stress Disorder. Via the Luminous Group, for the Silo, Georgia Davies.